Acumen Pharmaceuticals Inc (ABOS)

Apr 2, 2025, 7:00 AM EDT - 23 days ago

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Mar 27, 2025, 10:05 AM EDT - 4 weeks ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 4:00 PM EDT - 5 weeks ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 18, 2025, 8:48 AM EDT - 5 weeks ago

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's

Mar 12, 2025, 8:00 AM EDT - 6 weeks ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting

Mar 10, 2025, 4:00 PM EDT - 6 weeks ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 26, 2024, 4:00 PM EST - 5 months ago

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 1:17 PM EST - 5 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:00 PM EST - 5 months ago

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 4:00 PM EST - 6 months ago

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:05 AM EDT - 6 months ago

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

Oct 23, 2024, 8:00 AM EDT - 6 months ago

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 15, 2024, 8:00 AM EDT - 6 months ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

LENZ

Sep 30, 2024, 4:00 PM EDT - 7 months ago

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Sep 25, 2024, 4:00 PM EDT - 7 months ago

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Sep 3, 2024, 4:00 PM EDT - 8 months ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

Aug 13, 2024, 11:17 AM EDT - 9 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:00 PM EDT - 9 months ago

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

Jul 29, 2024, 8:38 PM EDT - 9 months ago

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 29, 2024, 7:00 AM EDT - 9 months ago

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease

Jul 28, 2024, 7:30 AM EDT - 9 months ago

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

May 14, 2024, 12:46 PM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 13, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 8, 2024, 5:47 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

May 7, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Apr 16, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

Mar 26, 2024, 10:45 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Mar 19, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

Mar 12, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

Mar 8, 2024, 8:50 AM EST - 1 year ago

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 21, 2024, 8:00 AM EST - 1 year ago

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 1, 2024, 7:00 AM EST - 1 year ago

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Jan 4, 2024, 4:15 PM EST - 1 year ago

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 4:29 PM EST - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:00 AM EST - 1 year ago

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Nov 13, 2023, 7:00 AM EST - 1 year ago

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 6, 2023, 4:01 PM EST - 1 year ago

Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023

Nov 6, 2023, 7:30 AM EST - 1 year ago

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

Nov 2, 2023, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

Oct 4, 2023, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's During Symposium at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD)

Oct 3, 2023, 11:03 AM EDT - 1 year ago

Navigating Acumen's Alzheimer's Risk And Reward

Oct 3, 2023, 5:15 AM EDT - 1 year ago

Acumen Pharmaceuticals: Novel Alzheimer's Molecule With Positive Early Data

Sep 19, 2023, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Sep 6, 2023, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

Aug 11, 2023, 9:52 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights